Synopsis of recent research by authors named "Dong-Hui Teng"
- Dong-Hui Teng's recent research primarily focuses on the efficacy and safety of biosimilar medications, specifically investigating QL1206, a denosumab biosimilar, for treating osteoporosis in postmenopausal women at high risk of fractures.
- In a phase III randomized, double-blind, placebo-controlled trial involving 455 participants, the study demonstrated that QL1206 significantly improved bone mineral density (BMD) in the lumbar spine compared to placebo over a 12-month period.
- The findings suggest that QL1206 could be a viable treatment option for postmenopausal women with osteoporosis, potentially enhancing patient care in this demographic within the Chinese population.
